Comparative Pharmacology
Head-to-head clinical analysis: ENFLONSIA versus ISOFLURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLONSIA versus ISOFLURANE.
ENFLONSIA vs ISOFLURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
None Documented
None Documented
Clinical Note
moderateIsoflurane + Torasemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide."
Clinical Note
moderateIsoflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid."
Clinical Note
moderateIsoflurane + Furosemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide."
Clinical Note
moderateIsoflurane + Bumetanide
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Bumetanide."